Literature DB >> 33758856

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.

Allison J Greaney, Tyler N Starr, Christopher O Barnes, Yiska Weisblum, Fabian Schmidt, Marina Caskey, Christian Gaebler, Alice Cho, Marianna Agudelo, Shlomo Finkin, Zijun Wang, Daniel Poston, Frauke Muecksch, Theodora Hatziioannou, Paul D Bieniasz, Davide F Robbiani, Michel C Nussenzweig, Pamela J Bjorkman, Jesse D Bloom.   

Abstract

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasma, including plasma from individuals from whom some of the antibodies were isolated. The plasma-escape maps most closely resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is dominated by a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

Entities:  

Year:  2021        PMID: 33758856      PMCID: PMC7987015          DOI: 10.1101/2021.03.17.435863

Source DB:  PubMed          Journal:  bioRxiv


  41 in total

1.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

2.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.

Authors:  Jun Lan; Jiwan Ge; Jinfang Yu; Sisi Shan; Huan Zhou; Shilong Fan; Qi Zhang; Xuanling Shi; Qisheng Wang; Linqi Zhang; Xinquan Wang
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962

3.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

Authors:  Zijun Wang; Fabian Schmidt; Yiska Weisblum; Frauke Muecksch; Christopher O Barnes; Shlomo Finkin; Dennis Schaefer-Babajew; Melissa Cipolla; Christian Gaebler; Jenna A Lieberman; Thiago Y Oliveira; Zhi Yang; Morgan E Abernathy; Kathryn E Huey-Tubman; Arlene Hurley; Martina Turroja; Kamille A West; Kristie Gordon; Katrina G Millard; Victor Ramos; Justin Da Silva; Jianliang Xu; Robert A Colbert; Roshni Patel; Juan Dizon; Cecille Unson-O'Brien; Irina Shimeliovich; Anna Gazumyan; Marina Caskey; Pamela J Bjorkman; Rafael Casellas; Theodora Hatziioannou; Paul D Bieniasz; Michel C Nussenzweig
Journal:  Nature       Date:  2021-02-10       Impact factor: 69.504

4.  Structural basis of a shared antibody response to SARS-CoV-2.

Authors:  Meng Yuan; Hejun Liu; Nicholas C Wu; Chang-Chun D Lee; Xueyong Zhu; Fangzhu Zhao; Deli Huang; Wenli Yu; Yuanzi Hua; Henry Tien; Thomas F Rogers; Elise Landais; Devin Sok; Joseph G Jardine; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2020-07-13       Impact factor: 47.728

5.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.

Authors:  Yunlong Cao; Bin Su; Xianghua Guo; Wenjie Sun; Yongqiang Deng; Linlin Bao; Qinyu Zhu; Xu Zhang; Yinghui Zheng; Chenyang Geng; Xiaoran Chai; Runsheng He; Xiaofeng Li; Qi Lv; Hua Zhu; Wei Deng; Yanfeng Xu; Yanjun Wang; Luxin Qiao; Yafang Tan; Liyang Song; Guopeng Wang; Xiaoxia Du; Ning Gao; Jiangning Liu; Junyu Xiao; Xiao-Dong Su; Zongmin Du; Yingmei Feng; Chuan Qin; Chengfeng Qin; Ronghua Jin; X Sunney Xie
Journal:  Cell       Date:  2020-05-18       Impact factor: 41.582

6.  The antigenic anatomy of SARS-CoV-2 receptor binding domain.

Authors:  Wanwisa Dejnirattisai; Daming Zhou; Helen M Ginn; Helen M E Duyvesteyn; Piyada Supasa; James Brett Case; Yuguang Zhao; Thomas S Walter; Alexander J Mentzer; Chang Liu; Beibei Wang; Guido C Paesen; Jose Slon-Campos; César López-Camacho; Natasha M Kafai; Adam L Bailey; Rita E Chen; Baoling Ying; Craig Thompson; Jai Bolton; Alex Fyfe; Sunetra Gupta; Tiong Kit Tan; Javier Gilbert-Jaramillo; William James; Michael Knight; Miles W Carroll; Donal Skelly; Christina Dold; Yanchun Peng; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Paul Klenerman; Nigel Temperton; David R Hall; Mark A Williams; Neil G Paterson; Felicity K R Bertram; C Alistair Siebert; Daniel K Clare; Andrew Howe; Julika Radecke; Yun Song; Alain R Townsend; Kuan-Ying A Huang; Elizabeth E Fry; Juthathip Mongkolsapaya; Michael S Diamond; Jingshan Ren; David I Stuart; Gavin R Screaton
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

7.  Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.

Authors:  Christoph Kreer; Matthias Zehner; Timm Weber; Meryem S Ercanoglu; Lutz Gieselmann; Cornelius Rohde; Sandro Halwe; Michael Korenkov; Philipp Schommers; Kanika Vanshylla; Veronica Di Cristanziano; Hanna Janicki; Reinhild Brinker; Artem Ashurov; Verena Krähling; Alexandra Kupke; Hadas Cohen-Dvashi; Manuel Koch; Jan Mathis Eckert; Simone Lederer; Nico Pfeifer; Timo Wolf; Maria J G T Vehreschild; Clemens Wendtner; Ron Diskin; Henning Gruell; Stephan Becker; Florian Klein
Journal:  Cell       Date:  2020-07-13       Impact factor: 41.582

8.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Authors:  Davide F Robbiani; Christian Gaebler; Frauke Muecksch; Julio C C Lorenzi; Zijun Wang; Alice Cho; Marianna Agudelo; Christopher O Barnes; Anna Gazumyan; Shlomo Finkin; Thomas Hägglöf; Thiago Y Oliveira; Charlotte Viant; Arlene Hurley; Hans-Heinrich Hoffmann; Katrina G Millard; Rhonda G Kost; Melissa Cipolla; Kristie Gordon; Filippo Bianchini; Spencer T Chen; Victor Ramos; Roshni Patel; Juan Dizon; Irina Shimeliovich; Pilar Mendoza; Harald Hartweger; Lilian Nogueira; Maggi Pack; Jill Horowitz; Fabian Schmidt; Yiska Weisblum; Eleftherios Michailidis; Alison W Ashbrook; Eric Waltari; John E Pak; Kathryn E Huey-Tubman; Nicholas Koranda; Pauline R Hoffman; Anthony P West; Charles M Rice; Theodora Hatziioannou; Pamela J Bjorkman; Paul D Bieniasz; Marina Caskey; Michel C Nussenzweig
Journal:  Nature       Date:  2020-06-18       Impact factor: 69.504

9.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.

Authors:  Philip J M Brouwer; Tom G Caniels; Karlijn van der Straten; Jonne L Snitselaar; Yoann Aldon; Sandhya Bangaru; Jonathan L Torres; Nisreen M A Okba; Mathieu Claireaux; Gius Kerster; Arthur E H Bentlage; Marlies M van Haaren; Denise Guerra; Judith A Burger; Edith E Schermer; Kirsten D Verheul; Niels van der Velde; Alex van der Kooi; Jelle van Schooten; Mariëlle J van Breemen; Tom P L Bijl; Kwinten Sliepen; Aafke Aartse; Ronald Derking; Ilja Bontjer; Neeltje A Kootstra; W Joost Wiersinga; Gestur Vidarsson; Bart L Haagmans; Andrew B Ward; Godelieve J de Bree; Rogier W Sanders; Marit J van Gils
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

10.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

Authors:  Alexandra Schäfer; Frauke Muecksch; Julio C C Lorenzi; Sarah R Leist; Melissa Cipolla; Stylianos Bournazos; Fabian Schmidt; Rachel M Maison; Anna Gazumyan; David R Martinez; Ralph S Baric; Davide F Robbiani; Theodora Hatziioannou; Jeffrey V Ravetch; Paul D Bieniasz; Richard A Bowen; Michel C Nussenzweig; Timothy P Sheahan
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.